BioWorld MedTech

Feb. 8, 2016

View Archived Issues

Boston Scientific's CRM suffers in 4Q, but near-term improvement is expected

Competition from Medtronic plc hurt Boston Scientific Corp.'s cardiac rhythm management (CRM) business in the fourth quarter, analysts noted after Boston Scientific reported its earnings for the quarter. Read More

Medtronic brings home FDA approval for MRI conditional CRT-D technology

Read More

WPS proposes noncoverage for cardiovascular risk panels

Read More

Labgenomics aggressively expands into global markets

Read More

Viral or bacterial? Febridx differentiates to mitigate antibiotic overuse

Read More

MDD's Company Stock Report

Read More

Other news to note

Read More

Financings

Read More

Product briefs

Read More

MDD's Neurology Extra

Read More